Abstract The adenosine antagonist 7-methylxanthine (7-mx) works against myopia in animal
models. In a clinical trial, 68 myopic children (mean age 11.3 years) received either placebo …

Purpose: Previous studies suggest that the adenosine receptor antagonist, 7-methylxanthine
(7-MX), retards myopia progression. Our aim was to determine whether 7-MX alters the …

Purpose Myopia is associated with an increased risk of permanent vision loss. The caffeine
metabolite 7-methylxanthine (7-MX), licensed in Denmark since 2009 as a treatment to …

Myopia is a widespread and complex refractive error in which a person's ability to see
distant objects clearly is impaired. Its prevalence rate is increasing worldwide, and as per …

High myopia is a major cause of uncorrectable visual impairment. It imposes major
challenges and costs for refractive correction, and for the treatment of associated …

AIM To determine the effect of 7-methylxanthine (7-MX) on the posterior sclera of form-
deprivation myopia (FDM) in pigmented rabbits. METHODS Sixteen pigmented rabbits were …

Purpose: The aim of this study was to determine the effect of the adenosine receptor
antagonist 7‐methylxanthine (7‐MX) on form deprivation myopia in 3‐week‐old guinea pigs …

Four hundred myopic children randomly received atropine 0.02%(n= 138) or 0.01%(n= 142)
in both eyes once-nightly or only wore single-vision spectacles (control group)(n= 120) for 2 …

Objectives: Myopia is the most common ocular disorder associated with increasing risk for
chorioretinal degeneration, retinal detachment, and other vision-threatening abnormalities …

Purpose To investigate the clinical efficacy of 0.01% atropine in slowing the progression of
myopia in children and to evaluate the influence of 0.01% atropine on secretion of basal tear …